SCHEMBL2364475

SCHEMBL2364475

CNC(=O)Cc1cc(OC)c(C(C)(C)C)cc1-c1ccc[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
GAA P10253 3/20 0.36
KDM4E B2RXH2 2/20 0.35
GPR55 Q9Y2T6 1/20 0.35
TNF P01375 1/20 0.34
IMPDH2 P12268 1/20 0.34
IMPDH1 P20839 1/20 0.34
CYP1A1 P04798 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTR2A P28223 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
BLM P54132 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NR1H4 Q96RI1 2/20 0.34
EPHX2 P34913 1/20 0.34
ALPL P05186 1/20 0.34
MTNR1A P48039 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2354510 0.88 CYP3A4 (0.41) CYP3A4GAAKDM4EIMPDH2IMPDH1
SCHEMBL2364691 0.87 ICMT (0.44) CYP3A4TNFIMPDH2IMPDH1CYP1A1
SCHEMBL3308176 0.85 CYP3A4 (0.42) CYP3A4GAAKDM4EIMPDH2IMPDH1
SCHEMBL2363467 0.84 CYP3A4 (0.43) CYP3A4GAAKDM4EIMPDH2IMPDH1
SCHEMBL2362800 0.83 CYP3A4 (0.44) CYP3A4GAAKDM4ETNFIMPDH2
SCHEMBL2362428 0.82 CYP3A4 (0.44) CYP3A4GAAKDM4EIMPDH2IMPDH1
SCHEMBL2363082 0.82 HTR2A (0.44) CYP3A4GAAKDM4EIMPDH2IMPDH1
SCHEMBL2352880 0.82 CYP3A4 (0.42) CYP3A4CYP1A1HTR2APOLBMAPT
SCHEMBL2354460 0.82 EPHX2 (0.44) CYP3A4GAAMAPTNR1H4EPHX2
SCHEMBL2362083 0.81 PLK1 (0.38) CYP3A4GAAKDM4EIMPDH2IMPDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885GAA 2099/4885KDM4E 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.